Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode.
about
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapyThe International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disordersTreatment response in relation to subthreshold bipolarity in patients with major depressive disorder receiving antidepressant monotherapy: a post hoc data analysis (KOMDD study).Antidepressant treatment for acute bipolar depression: an update.Broadening the diagnosis of bipolar disorder: benefits vs. risks.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective studyShort-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate.Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder.The clinical management of bipolar disorder complexity using a stratified model.An update on antidepressant use in bipolar depression.Efficacy and safety of fluoxetine monotherapy in bipolar depression: a systematic review.Rapid versus non-rapid cycling bipolar II depression: response to venlafaxine and lithium and hypomanic risk.Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression: A Randomized Clinical Trial.Treatment of bipolar depression
P2860
Q21560915-B5D3B362-39D7-4C33-84B7-21A8DB26D871Q30583384-118ADB02-50D7-412B-BEFD-27E47CE24680Q31106370-1D82DE66-C7D1-4F6B-BA4B-5EF16FA366DDQ34154885-332E1F0F-3E7F-4BF1-A68A-83371E5BAD8CQ35285927-07705406-C511-4A41-826A-FF268CCE28F6Q35862776-2CBF5E8E-130F-4F20-A9C9-60ABAE9558E5Q35967580-E8DD91B3-410F-4FE6-884C-3C5D980651D5Q36754503-B313C398-442B-40A5-A9A7-A23A6CEFF6E5Q38003196-F5F15ACD-6EA8-4448-A9C5-DF0BC3045D9FQ38003199-88AF8FF0-6620-4A3A-A3F0-EA3C3F8285E2Q38052088-2FBB9301-F8BD-4A89-832D-DA7C4021D948Q38092894-1AD4FD78-029D-4CAA-9987-BA964D64509AQ41842899-8F9BBD5B-D60E-449A-8B97-BF08BBEAE714Q44142664-BC280A0F-0882-454A-9A03-F230644F82BBQ47241220-FDB44513-A124-433C-9CF3-3C390A6762A9Q57730484-DEDE333E-EC2C-43CC-A4F7-737B89E30D18
P2860
Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efficacy and mood conversion r ...... r II major depressive episode.
@ast
Efficacy and mood conversion r ...... r II major depressive episode.
@en
type
label
Efficacy and mood conversion r ...... r II major depressive episode.
@ast
Efficacy and mood conversion r ...... r II major depressive episode.
@en
prefLabel
Efficacy and mood conversion r ...... r II major depressive episode.
@ast
Efficacy and mood conversion r ...... r II major depressive episode.
@en
P2860
P1476
Efficacy and mood conversion r ...... r II major depressive episode.
@en
P2093
Jay D Amsterdam
Justine Shults
P2860
P304
P356
10.1097/JCP.0B013E3181DA5300
P407
P577
2010-06-01T00:00:00Z